Mayo Clinic researchers conducted a randomized, double-blind Phase II study involving patients with type 2 diabetes and found that those who received the oral hepatoselective glucokinase activator TTP399 had a clinically significant and sustained A1C reduction from baseline, compared with those on placebo. The findings in Science Translational Medicine also revealed that those who received TTP399 at 800 mg/day had reduced fasting plasma glucagon, increased HDL cholesterol, and reduced weight among patients weighing at least 100 kg.
Study examines efficacy of oral hepatoselective GKA in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.